Skip to main content

Table 2 Tumor and treatment characteristics

From: 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

  FDG study (N = 22) FLT study (N = 27)
N (%) Mean (range) N (%) Mean (range)
Diagnosis
 Invasive ductal 20 (91%)   20 (74%)  
 Invasive lobular 2 (9%)   7 (26%)  
Tumor size (cm)   2.6 (0.7–7.5)   3.1 (1.1–7.6)*
T Stage
 T1 9 (41%)   8 (30%)  
 T2 12 (55%)   15 (56%)  
 T3 1 (5%)   3 (11%)  
 X   1 (4%)  
ER+ 22 (100%)   27 (100%)  
PR+ 20 (91%)   22 (81%)  
Her2- 22 (100%)   26 (96%)  
Ki-67 (Biopsy)
 All   25.4 (1.0–72.9)   20.6 (4–54)
 Ductal   26.5 (1–72.9)   23.5 (6–54)
 Lobular   14 (9.2–18.8)   12.3 (4–23)
Ki-67 (at surgery)
 All   8.7 (1.0–31.4)   7.9 (0–41)
 Ductal   9.1 (< 1.0–31.4)   9.3 (0–41)
 Lobular   4.4 (3–5.9)   4.1 (0–20.3)
Ki-67 ≤ 10% (at surgery)
 All 17 (77%)   21 (78%)  
Ductal 15 (75%)   15 (75%)  
 Lobular 2 (100%)   6 (86%)  
  1. *Tumor sized by MRI in all but one patient. That patient had a lesion size of 1.1 cm by contrast enhanced CT
  2. 1 patient was scored as HER2 equivocal, but no plan for treatment change